A long-term study supports the ingredient's safe use in formula.
Inulin may allow infant formula to more closely mimic the bacterial composition of human breast milk, but health bodies have expressed concern over whether the prebiotic may cause watery stools and other adverse effects in infants. A new study on the long-term safety of inulin-enriched formula may help to quell this concern.
In a study sponsored by inulin supplier Beneo GmbH (Mannheim, Germany), university researchers analyzed the stools of 131 infants on control formula or formula with oligofructose-enriched inulin (Synergy1) from birth to four months of age. Stools were assessed for frequency, water balance, and bacterial compositions, and compared to those of 57 breastfed infants.
Infants who consumed the inulin-enriched formula experienced softer and more frequent stools than infants on control formula, but this was not associated with an impaired water balance. Adverse event reports and anthropometry parameters were no different for each group.
Diederick Meyer, PhD, is the manager of scientific and regulatory affairs for Sensus (Roosendaal, the Netherlands), another inulin supplier. He says that while health bodies have expressed concern over potential adverse effects of inulin in formula, they have still gone ahead and cleared some ingredients for this use. The EU approved a long-chain inulin for formula use years ago, and FDA recently had no questions in response to a Beneo GRAS application for formula-intended oligofructose.
“Also, data for other prebiotic ingredients show that they may have a positive effect on the fecal flora composition of infants of various ages without adverse effects,” says Meyer. “As an example, native Frutafit inulin from Sensus was tested in infants with average 13 weeks and 8 months, showing a bifidogenic effect without significant adverse effects on stool consistency.”
In the Beneo study, the bacterial profile of the inulin group’s stools more closely resembled that of breastfed infants, with a trend towards high levels of health-promoting Bifidobacteria.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
Balchem’s Newest Launch Optifolin⁺® Brings Innovation to the Folate Market
September 19th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin⁺, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
Women in Nutraceuticals to hold first annual WIN Awards at SupplySide West 2024
October 16th 2024According to the organization’s press release, the awards program is designed to “celebrate the remarkable contributions and achievements of those who champion gender equity, drive research innovations, excel in mentorship within the nutraceutical sector, and significantly contribute to WIN’s programs.”
Kyowa Hakko USA to share new research on its Cognizin citicoline ingredient at SupplySide West 2024
Published: October 15th 2024 | Updated: October 15th 2024According to the company, the new research demonstrates the ingredient’s neuroprotective qualities and potential to enhance cognitive function, and support healthy brain aging.